EntryPoint Capital LLC Invests $380,000 in Tourmaline Bio, Inc. $TRML

Key Points

• EntryPoint Capital LLC has invested $380,000 in Tourmaline Bio, acquiring 24,972 shares, representing about 0.10% of the company's stock.
• Multiple institutional investors, including Tower Research Capital and GAMMA Investing, have significantly increased their stakes in Tourmaline Bio, with combined ownership by institutional investors at approximately 91.89%.
• Analysts have a consensus rating of "Buy" for Tourmaline Bio, with target prices ranging from $50.00 to $70.00 as indicated by various research firms.

EntryPoint Capital LLC acquired a new position in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 24,972 shares of the company's stock, valued at approximately $380,000. EntryPoint Capital LLC owned about 0.10% of Tourmaline Bio as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of TRML. Tower Research Capital LLC TRC boosted its stake in Tourmaline Bio by 297.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock worth $33,000 after purchasing an additional 1,232 shares in the last quarter. Virtus ETF Advisers LLC acquired a new stake in Tourmaline Bio in the 4th quarter worth approximately $64,000. Brooklyn Investment Group boosted its stake in Tourmaline Bio by 148.9% in the 1st quarter. Brooklyn Investment Group now owns 3,923 shares of the company's stock worth $60,000 after purchasing an additional 2,347 shares in the last quarter. GAMMA Investing LLC boosted its stake in Tourmaline Bio by 4,481.7% in the 1st quarter. GAMMA Investing LLC now owns 7,514 shares of the company's stock worth $114,000 after purchasing an additional 7,350 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in Tourmaline Bio in the 1st quarter worth approximately $158,000. Hedge funds and other institutional investors own 91.89% of the company's stock.

Tourmaline Bio Trading Up 0.4%

Shares of NASDAQ TRML opened at $22.46 on Thursday. Tourmaline Bio, Inc. has a 12 month low of $11.56 and a 12 month high of $29.79. The company has a 50 day simple moving average of $19.25 and a two-hundred day simple moving average of $16.69. The stock has a market cap of $576.89 million, a price-to-earnings ratio of -6.55 and a beta of 2.04.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.04. Analysts forecast that Tourmaline Bio, Inc. will post -3.02 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on TRML. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Tourmaline Bio in a research note on Monday, May 5th. Chardan Capital reiterated a "buy" rating and issued a $70.00 target price on shares of Tourmaline Bio in a research note on Thursday, August 14th. Finally, Guggenheim reiterated a "buy" rating and issued a $55.00 target price on shares of Tourmaline Bio in a research note on Thursday, August 14th. Seven analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $50.14.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.

Want to see what other hedge funds are holding TRML? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.